Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study

Letter Gastroenterology & Hepatology

Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD

Abraham S. Meijnikman et al.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question

Thomas Marjot et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Markus Cornberg et al.

Summary: According to a recent estimate by the World Health Organization, the SARS-CoV-2 pandemic has affected nearly 100 million people globally, with patients with chronic liver diseases (CLD) at higher risk of infections. Vaccination against various pathogens, including SARS-CoV-2, is important for these patients, although impaired immune responses may affect the efficacy of immunization. The safety, immunogenicity, and efficacy of SARS-CoV-2 vaccines in patients with CLD, cirrhosis, hepatobiliary cancer, and liver transplant recipients still require further study.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Letter Gastroenterology & Hepatology

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis

Yu-Jie Zhou et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Letter Gastroenterology & Hepatology

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Dong Ji et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study

Related references

Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Export Citation

Share Paper